BioCryst Pharmaceuticals Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de BioCryst Pharmaceuticals de 70.3% y 15.5% respectivamente, mientras que el BPA crecerá en un 70.1% al año.

Información clave

70.3%

Tasa de crecimiento de los beneficios

70.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	15.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	06 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Aug 08

Recent updates

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Aug 08

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 21

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

May 07

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

Apr 29

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Feb 27

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jan 09

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

Jun 08

BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks

Aug 18

BioCryst Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

BioCryst Pharmaceuticals: Waiting For Clarity

Jul 25

BioCryst: A Prudent Diversification

Jun 24

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:BCRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	601	46	191	N/A	7
12/31/2025	515	-41	82	-8	9
12/31/2024	433	-79	4	-50	8
6/30/2024	382	-146	-86	-84	N/A
3/31/2024	355	-209	-104	-101	N/A
12/31/2023	331	-227	-97	-95	N/A
9/30/2023	318	-236	-112	-110	N/A
6/30/2023	307	-243	-124	-123	N/A
3/31/2023	290	-226	-133	-132	N/A
12/31/2022	271	-247	-163	-162	N/A
9/30/2022	238	-193	-172	-170	N/A
6/30/2022	204	-210	-163	-161	N/A
3/31/2022	188	-194	-162	-159	N/A
12/31/2021	157	-184	-145	-142	N/A
9/30/2021	114	-227	-154	-152	N/A
6/30/2021	79	-214	-168	-167	N/A
3/31/2021	32	-209	-173	-173	N/A
12/31/2020	18	-183	-136	-135	N/A
9/30/2020	54	-125	-103	-103	N/A
6/30/2020	49	-116	-93	-92	N/A
3/31/2020	48	-115	-86	-86	N/A
12/31/2019	49	-109	-90	-90	N/A
9/30/2019	12	-134	-103	-103	N/A
6/30/2019	12	-126	-111	-111	N/A
3/31/2019	23	-107	-100	-100	N/A
12/31/2018	21	-101	-93	-93	N/A
9/30/2018	22	-93	-79	-79	N/A
6/30/2018	29	-79	-57	-56	N/A
3/31/2018	20	-77	N/A	-52	N/A
12/31/2017	25	-66	N/A	-41	N/A
9/30/2017	30	-51	N/A	-36	N/A
6/30/2017	29	-47	N/A	-42	N/A
3/31/2017	31	-47	N/A	-43	N/A
12/31/2016	26	-55	N/A	-53	N/A
9/30/2016	22	-69	N/A	-62	N/A
6/30/2016	25	-72	N/A	-58	N/A
3/31/2016	46	-51	N/A	-28	N/A
12/31/2015	48	-43	N/A	-13	N/A
9/30/2015	49	-37	N/A	-12	N/A
6/30/2015	41	-31	N/A	-8	N/A
3/31/2015	17	-50	N/A	-33	N/A
12/31/2014	14	-45	N/A	-39	N/A
9/30/2014	19	-39	N/A	-29	N/A
6/30/2014	18	-38	N/A	-28	N/A
3/31/2014	17	-36	N/A	-24	N/A
12/31/2013	17	-30	N/A	-27	N/A
9/30/2013	11	-36	N/A	-29	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BCRX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.5%).

Beneficios vs. Mercado: Se prevé que BCRX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que BCRX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (15.5% al año) de BCRX crezcan más rápidamente que los del mercado US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 15.5% al año) de BCRX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BCRX se prevé que sea elevada dentro de 3 años.

BioCryst Pharmaceuticals Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus estimates of losses per share improve by 41%

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.60 loss

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Recent updates

BioCryst Pharmaceuticals, Inc. Announces Successfully Completed Negotiations with the Pan-Canadian Pharmaceutical Alliance (Pcpa) for Oral, Once-Daily Prorladeyo® (Berotralstat)

Biocryst Pharmaceuticals, Inc. Appoints Donald Fong as Chief Medical Officer

Consensus estimates of losses per share improve by 41%

Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioCryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Senior VP recently bought US$202k worth of stock

BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO

Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024

BioCryst: Estimate-Beating Q1 But Risks Are Considerable

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price

BioCryst Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

BioCryst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 06, 2024

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

Consensus EPS estimates upgraded to US$0.60 loss

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Price target decreased by 13% to US$12.20

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

Full year 2023 earnings: EPS misses analyst expectations

BioCryst Launches Orladeyo (Berotralstat) in Italy

BioCryst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 26, 2024

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Forecast breakeven date pushed back to 2026

BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

BioCryst Pharmaceuticals, Inc. Announces Publication of Data from Open-Label Extension of the APeX-2 Pivotal Trial of ORLADEYO(R) (berotralstat)

Biocryst Pharmaceuticals, Inc. Announces Retirement of Kenneth B. Lee from the Board of Directors, Effective December 31, 2023

Biocryst Announces Approval of Orladeyo®? (Berotralstat) by the National Administration of Drugs, Foods, and Medical Devices in Argentina

BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO

Price target decreased by 7.3% to US$14.09

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)

New minor risk - Shareholder dilution

No longer forecast to breakeven

BioCryst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2023

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.23 loss in 3Q 2022)

No longer forecast to breakeven

BioCryst Pharmaceuticals, Inc. to Present New ORLADEYO®? (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Biocryst Pharmaceuticals, Inc. Begins Enrollment in Proof-Of-Concept Trial to Confirm Safe, Effective, Once-Daily Dose of Oral Factor D Inhibitor, Bcx10013

BioCryst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Consensus EPS estimates fall by 16%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioCryst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Biocryst Pharmaceuticals, Inc. Announces Executive Changes

BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business

BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Public Health Institute of Chile

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CEO, President & Executive Director exercised options to buy US$264k worth of stock.

Consensus EPS estimates fall by 13%

Price target decreased by 7.5% to US$15.45

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

BioCryst Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 21, 2023

CEO, President & Executive Director exercised options and sold US$493k worth of stock

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating Orladeyo(R) (Berotralstat) in Pediatric Patients with Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

Forecast to breakeven in 2025

CEO, President & Executive Director exercised options and sold US$3.4m worth of stock

BioCryst Pharmaceuticals, Inc. Announces Approval of Orladeyo® (Berotralstat) by the Israeli Ministry of Health

Chief Discovery Officer exercised options and sold US$393k worth of stock

High number of new directors

Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biocryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

BioCryst Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo

BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer